The presence of miR-186-5p has been linked to drug resistance in treatments such as cisplatin, methotrexate, and taxol by targeting twist-related protein-1 (TWIST-1), a major EMT-related transcription factor in breast cancer [84] and gastric cancer [85,86]. This evidence concerns the gene TWIST1 and breast carcinoma.